We passionately improve health
Boehringer Ingelheim is a global, research-driven pharmaceutical company
embracing many cultures and diverse societies.
THERAPEUTIC AREA
Cardiovascular
Cardiovascular disease
including
heart disease
and stroke
is a major
global health concern and the leading cause of death and disability worldwide1
Cardiovascular disease, including heart disease and
stroke, is a major global health concern and the leading cause of death and disability
worldwide1. At Boehringer Ingelheim we address unmet medical need by providing innovative
treatments that improve the care of patients suffering from a range of cardiovascular conditions
including irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs
(deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack
(myocardial infarction).
Learn more
1 Vilahur G et al. Eur Heart J Suppl 2014; 16(Suppl_A): A7-A11.
Learn more
Metabolic
2.3
million people
About 2.3 million people in South Africa were living with type 2 diabetes in 2015 accounting for 7% of the population.>
About 2.3 million people in South Africa were
living with type 2 diabetes in 2015 accounting for 7% of the population. This number is
projected to increase to 4 million by 2035, a 55% increase in prevalence, the biggest driver
being obesity. Type 2 diabetes is a chronic, progressive condition and long term complications
include strokes, heart attack, and cardiovascular death, as well as diabetic kidney disease,
retinopathy, arm and leg amputation, and autonomic neuropathy. In addition to the now marketed
products from our own R & D we are also focussed cardio-metabolic indications with a high
unmet medical need. Learn more
